Results 271 to 280 of about 1,795,367 (304)
Some of the next articles are maybe not open access.
Immunotherapy in acute myeloid leukemia
Cancer, 2015Despite the remarkable progress made in some leukemias such as CML and CLL, cytotoxic treatment for AML remains essentially unchanged over the last 4 decades. Several lines of evidence, including the graft versus leukemia effect associated with allogeneic hematopoietic stem cell transplantation (HSCT), suggest that immunotherapy is an active modality ...
Dolores A, Grosso +2 more
openaire +2 more sources
Decitabine for acute myeloid leukemia
Expert Review of Anticancer Therapy, 2012Decitabine (Dacogen(®), Eisai Inc., NJ, USA) is a nucleoside analogue DNA methyltransferase inhibitor first synthesized and documented to have antileukemic efficacy over 40 years ago. Over the years, the dosing of decitabine has been refined, such that for acute myeloid leukemia, a 5-day schedule of 20 mg/m(2) is now commonly utilized.
openaire +2 more sources
Pediatric acute myeloid leukemia [PDF]
Expert Review of Anticancer Therapy, 2012 Pediatric acute myeloid leukemia (AML) is currently associated with survival rates as high as 70%. However, many events still occur, side effects are significant, and late effects occur and can even be life-threatening. Thus, the treatment of pediatric AML still needs further improvement.
openaire +4 more sources
Childhood Acute Myeloid Leukemia
Current Treatment Options in Oncology, 2008Despite the use of intensive chemotherapy and hematopoietic stem cell transplantation, approximately one-third of children with acute myeloid leukemia (AML) still suffer relapse of their disease. It is unlikely that improvements in outcome can be achieved by further intensification of conventional chemotherapy.
openaire +2 more sources
Acute myeloid leukemia in adults
Current Treatment Options in Oncology, 2000The treatment outcome for most adults with acute myeloid leukemia (AML) remains unacceptable. Additional agents or substitution of high-dose cytarabine for conventional-dose cytarabine during induction does not improve the remission rate or overall survival. There is substantial toxicity with high-dose cytarabine during induction.
L D, Cripe, S, Hinton
openaire +2 more sources
Immunohistochemistry in Acute Myeloid Leukemia
2017The World Health Organization's Classification of Tumours of Haematopoietic and Lymphoid Tissues (Swerdlow et al. (eds) WHO Classification of tumours of haematopoietic and lymphoid tissues, 4th edn. WHO Press, Lyon, 2008) created a classification scheme incorporating genetic, molecular, morphologic, and immunophenotypic characteristics.
openaire +2 more sources
Pathophysiology of Acute Myeloid Leukemia
Acta Haematologica<b><i>Background:</i></b> Acute myeloid leukemia (AML) is a biologically heterogenous disease arising in clonally proliferating hematopoietic stem cells. Sequential acquisition of mutations leads to expanded proliferation of clonal myeloid progenitors and failure of differentiation, leading to fulminant AML.
Franziska, Wachter, Yana, Pikman
openaire +2 more sources
New England Journal of Medicine, 1999
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources
Löwenberg, Bob, Downing, JR, Burnett, A
openaire +3 more sources
Acute myeloid leukemia in the elderly
Blood Reviews, 1998The optimal management of acute myeloid leukemia in patients over 60 years-of-age remains a controversial issue. The complete remission rates after conventional induction chemotherapy progressively decreases after the age of 60. This is explained by host-related factors and by differences in the biology of leukemia.
openaire +2 more sources